33,289 Shares in Xilio Therapeutics, Inc. (NASDAQ:XLO) Purchased by XTX Topco Ltd

XTX Topco Ltd acquired a new position in Xilio Therapeutics, Inc. (NASDAQ:XLO) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 33,289 shares of the company’s stock, valued at approximately $32,000. XTX Topco Ltd owned 0.08% of Xilio Therapeutics at the end of the most recent reporting period.

Separately, Renaissance Technologies LLC raised its position in Xilio Therapeutics by 18.3% in the 2nd quarter. Renaissance Technologies LLC now owns 295,000 shares of the company’s stock worth $280,000 after purchasing an additional 45,554 shares during the period. 54.29% of the stock is owned by hedge funds and other institutional investors.

Xilio Therapeutics Price Performance

Xilio Therapeutics stock opened at $0.75 on Thursday. Xilio Therapeutics, Inc. has a 1-year low of $0.49 and a 1-year high of $2.89. The firm has a market capitalization of $32.96 million, a P/E ratio of -0.29 and a beta of -0.10. The company’s 50-day moving average is $0.84 and its 200 day moving average is $0.97.

Xilio Therapeutics (NASDAQ:XLO) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.01). The company had revenue of $2.36 million for the quarter, compared to the consensus estimate of $30.00 million. Research analysts anticipate that Xilio Therapeutics, Inc. will post -1.26 earnings per share for the current fiscal year.

Xilio Therapeutics Company Profile

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.